India a global generic pharma powerhouse, irreplaceable for US: Pharmexcil

On July 31, Trump announced a 25% tariff on most of the goods exported from India to the US, citing an imbalance in bilateral trade. On August 6, he said the US will levy an additional 25% tariff on the same products, thereby increasing the tariff on Indian exports to 50%. Generic pharmaceuticals were exempted from this tariff hike, subject to the outcome of an ongoing investigation carried out by the US government to determine the effects on the national security of imports of pharmaceuticals and pharmaceutical ingredients, including finished drug products, critical inputs such as active pharmaceutical ingredients, and key starting materials etc.